VRCA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRCA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Verrica Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2024 was $-16.20 Mil. Verrica Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $0.34 Mil. Therefore, Verrica Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2024 was -4,709.88%.
The historical rank and industry rank for Verrica Pharmaceuticals's Pretax Margin % or its related term are showing as below:
The historical data trend for Verrica Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Pretax Margin % | Get a 7-Day Free Trial |
![]() |
- | -292.33 | -271.11 | -1,307.47 | -1,012.15 |
Verrica Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Pretax Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-1,238.13 | -531.39 | -331.97 | 1,283.55 | -4,709.88 |
For the Biotechnology subindustry, Verrica Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Pretax Margin % falls into.
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Verrica Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as
Pretax Margin | = | Pre-Tax Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -76.579 | / | 7.566 | |
= | -1,012.15 % |
Verrica Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
Pretax Margin | = | Pre-Tax Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -16.202 | / | 0.344 | |
= | -4,709.88 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals (NAS:VRCA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher G. Hayes | officer: General Counsel | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Ted White | director, officer: President and CEO | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Terry Kohler | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380 |
Joe Bonaccorso | officer: Chief Commercial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Gary Goldenberg | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
A Brian Davis | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Craig Ballaron | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Lawrence Eichenfield | director | C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502 |
Diem Nguyen | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Matt Davidson | 10 percent owner | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Linda Palczuk | officer: Chief Operating Officer | 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046 |
Chris Degnan | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
From GuruFocus
By Business Wire • 10-11-2024
By Marketwired • 12-06-2024
By Marketwired • 11-04-2024
By Marketwired • 05-27-2024
By Marketwired • 07-01-2024
By GuruFocus News • 11-06-2024
By Marketwired • 05-30-2024
By GuruFocus News • 03-12-2025
By Marketwired • 08-14-2024
By GuruFocus News • 02-13-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.